-
Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star Therapeutics Inc., (NASDAQ: FSTX), and Japan-based Takeda Pharmaceutical Co., Ltd. The agreement facilitates the utilization of F-star’s proprietary wholly human Fcab and tetravalent mAb2 platforms to develop next-generation multi-specific immunotherapies targeting cancer. Joint Research and…
-
3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus
•
China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products Administration (NMPA) in China for its nalfurafine orally disintegrating tablets. The drug is used to improve pruritus in hemodialysis patients in situations where existing treatment efficacy is not ideal. This marks the first and only…
-
Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements
•
China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot firm GL-Biotech in relation to GL-Biotech’s proprietary DisacLink technology. The collaboration aims to achieve technological breakthroughs, jointly develop, improve, and commercialize fixed-point conjugate technology, with both parties engaging in extensive commercial cooperation for the external…
-
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Esflurbiprofen Patch Clinical Study
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its esflurbiprofen patch, a generic version of Japan firm Taisho Pharmaceutical’s Loqoa tape. The intended indication for the patch…
-
Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with Pheon Therapeutics (Pheon), a leading UK-based antibody-drug conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers. According to the agreement, Pheon will develop and commercialize an antibody developed using Biocytogen’s proprietary…
-
Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy
•
Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with Leman Biotech Co., Ltd, a clinical-stage immune-metabolism drug developer based in Shenzhen. The collaboration aims to explore the application and translation capabilities of immune metabolism reprogramming technology (Meta 10) in solid tumor CAR-T therapy, with…
-
China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities
•
This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a dozen non-China-based multinational corporations (MNCs). Minister of Commerce Wang Wentao engaged with the attendees, hearing 25 individual suggestions and discussions on current market conditions from companies such as Bayer AG (ETR: BAYN), Novo Nordisk (NYSE:…
-
Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy
•
Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award in China for its lead pipeline candidate, Reqorsa (ONC-001/2) immunogene therapy. The China Intellectual Property Administration (CNIPA) has granted patent No: 201780076886.X, which covers the use of the therapy in combination with PD-1 antibodies, providing…
-
Moderna Inc. Plans USD 1 Billion Investment in Shanghai for mRNA Vaccine Production
•
US-based mRNA specialist Moderna Inc. (NASDAQ: MRNA) has revealed further details of its entry into the China market, with an agreement that vaccines manufactured locally will remain exclusively within the China market, as reported by Reuters based on an email response from a company spokesperson. This agreement is part of…
-
CSPC Pharmaceutical Group Receives Marketing Approval for Desvenlafaxine in China
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving marketing approval in China for its Category 3 product, desvenlafaxine, signifying that it has passed the generic quality and consistency evaluation (GQCE). Desvenlafaxine: A Third-Generation Anti-DepressantDesvenlafaxine is a third-generation anti-depressant that functions by inhibiting the reuptake mechanism of 5-hydroxytryptamine norepinephrine,…
-
AbbVie’s Rinvoq Receives NMPA Approval for Moderate to Severe Crohn’s Disease Treatment
•
US pharmaceutical firm AbbVie (NYSE: ABBV) has announced receiving market approval from the National Medical Products Administration (NMPA) for its Rinvoq (upadacitinib), a selective JAK inhibitor, to treat moderate to severe active Crohn’s disease in adult patients who have a poor or intolerant response or a contraindication to one or…
-
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
•
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its injectable goserelin acetate in microsphere form, a treatment for prostate cancer requiring androgen castration therapy. This innovative formulation is designed to provide a smoother drug release during the…
-
Huadong Medicine’s Liraglutide Biosimilar Gains NMPA Approval for Weight Loss Indication
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received additional indication approval from the National Medical Products Administration (NMPA) for its biosimilar version of Novo Nordisk’s (NYSE: NVO) Victoza (liraglutide). This glucagon-like peptide-1 (GLP-1) receptor agonist is now approved for use in weight loss management. Expanding…
-
Abbisko Therapeutics’ EGFR Inhibitor ABSK112 Clears FDA for Global Phase I NSCLC Study
•
Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a global Phase I clinical study for its next-generation EGFR inhibitor, ABSK112, in non-small cell lung cancer (NSCLC). This development highlights the company’s progress…
-
Jacobio Pharma’s KRAS Inhibitor Glecirasib Advances to Pivotal Pancreatic Cancer Trial
•
China-based Jacobio Pharma (HKG: 1167) has announced that it has received the green light from the National Medical Products Administration (NMPA) to initiate a pivotal clinical study for its novel KRAS G12C inhibitor, glecirasib, in pancreatic cancer. This development marks glecirasib as the world’s first KRAS inhibitor to reach the…
-
InnoCare Pharma Initiates Clinical Trial for TYK2 Inhibitor ICP-488 in Psoriasis Patients
•
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced a significant milestone in the clinical development of its TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, ICP-488, with the dosing of the first psoriasis patient in China. This marks a progressive step towards addressing the treatment needs for psoriasis and other…
-
ZAP-X Gyroscopic Radiosurgery Platform Receives NMPA Approval for Brain Tumor Treatment
•
US-based Zap Surgical Systems Inc. has announced that it has received market approval in China for its innovative ZAP-X Gyroscopic Radiosurgery Platform. This advanced system is designed for the treatment of brain tumors, lesions, and other head and neck conditions. The ZAP-X system utilizes unique gyroscopic mobility to direct radiosurgical…
-
NMPA Approves Pitolisant for Narcolepsy-Related Excessive Daytime Drowsiness and Cataplexy
•
The National Medical Products Administration (NMPA) has approved pitolisant as a treatment for excessive daytime drowsiness (EDS) or cataplexy in adults with narcolepsy. This marks a significant advancement in the therapeutic options available for narcolepsy patients in China. Pitolisant’s Mechanism of Action and International DesignationsPitolisant is a selective histamine 3…
-
Ascentage Pharma’s Olverembatinib Gets NMPA Greenlight for Phase III Study in Ph+ ALL
•
China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a pivotal regulatory Phase III clinical study. The study will evaluate the combination of its Category 1 drug, olverembatinib, with chemotherapy in newly diagnosed Philadelphia chromosome positive (Ph+) acute…
